| Status | In progress |
| Technology type | Medicine |
| Decision | Selected |
| Reason for decision | Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources |
| Process | STA Standard |
| ID number | 6153 |
Provisional Schedule
| Committee meeting | 11 June 2024 |
Project Team
| Project lead | Leena Issa |
Email enquiries
- If you have any queries please email TATeam7@nice.org.uk
| External Assessment Group | Centre for Reviews and Dissemination and Centre for Health Economics, University of York |
Stakeholders
| Companies sponsors | Novartis (ribociclib) |
| Others | Department of Health and Social Care |
| NHS England | |
| Patient carer groups | Black Health Agency for Equality |
| Breast Cancer Now | |
| Breast Cancer UK | |
| Cancer Black Care | |
| Cancer Equality | |
| Helen Rollason Cancer Charity | |
| Independent Cancer Patients Voice | |
| Inflammatory Breast Cancer Network UK | |
| Macmillan Cancer Support | |
| Maggie’s Centres | |
| Marie Curie | |
| MET UP UK | |
| South Asian Health Foundation | |
| Specialised Healthcare Alliance | |
| Tenovus Cancer Care | |
| Professional groups | Association of Breast Surgery |
| Association of Cancer Physicians | |
| British Geriatrics Society | |
| British Institute of Radiology | |
| British Oncology Pharmacy Association | |
| British Psychosocial Oncology Society | |
| Cancer Research UK | |
| Royal College of General Practitioners | |
| Royal College of Nursing | |
| Royal College of Physicians | |
| Royal College of Radiologists | |
| Royal Pharmaceutical Society | |
| Royal Society of Medicine | |
| Society and College of Radiographers | |
| UK Breast Cancer Group | |
| UK Clinical Pharmacy Association | |
| UK Oncology Nursing Society | |
| Associated public health groups | Public Health Wales |
| UK Health Security Agency | |
| Comparator companies | Eli Lily (abemaciclib) |
| AstraZeneca (olaparib) | |
| General commentators | All Wales Therapeutics and Toxicology Centre |
| Allied Health Professionals Federation | |
| Board of Community Health Councils in Wales | |
| British National Formulary | |
| Care Quality Commission | |
| Department of Health, Social Services and Public Safety for Northern Ireland | |
| Healthcare Improvement Scotland | |
| Medicines and Healthcare products Regulatory Agency | |
| National Association of Primary Care | |
| National Pharmacy Association | |
| NHS Confederation | |
| Scottish Medicines Consortium | |
| Welsh Government | |
| Welsh Health Specialised Services Committee | |
| Relevant research groups | Against Breast Cancer |
| Breast Cancer Hope | |
| Cochrane Breast Cancer Group | |
| Cochrane UK | |
| Genomics England | |
| Institute of Cancer Research | |
| MRC Clinical Trials Unit | |
| National Institute for Health Research | |
| Pro-Cancer Research Fund |
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 16 April 2024 | Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in late August 2024. These timings are based on a request from the company to reschedule the initial date set by NICE, in order to facilitate a suitably comprehensive and robust submission. |
| 15 January 2024 | Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in early July 2024. These timings are based on a request from the company to reschedule the initial date set by NICE, in order to better align with regulatory timelines and facilitate a suitably comprehensive and robust submission. |
| 30 October 2023 | Invitation to participate |
| 07 June 2023 - 05 July 2023 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
| 07 June 2023 | In progress. Scoping commenced |
| 27 March 2023 | Following the changes to remove technical engagement as standard from appraisal timelines, the timelines for the appraisal of Ribociclib with an aromatase inhibitor for adjuvant treatment of hormone receptor-positive, HER2-negative early breast cancer at risk of relapse have been revised. It is anticipated that the appraisal will begin in early-August 2023 when we will write to you about how you can get involved. |
| 11 July 2022 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual